Non-invasive Bioluminescence Monitoring of Hepatocellular Carcinoma Therapy in an HCR Mouse Model

Zhu Zhao, Juji Dai, Yan Yu, Qian Zhang, Sai Liu, Guanmeng Huang, Zheng Zhang, Tianke Chen, Rulu Pan, Liting Lu, Wenyi Zhang, Wanqin Liao, Xincheng LuFrontiers in Oncology 2019 · DOI

Abstract

Animal models play crucial roles in the development of anticancer therapeutics. The ability to quickly assess the localized primary hepatocellular carcinoma (HCC) status in a non-invasive manner would significantly improve the effectiveness of anti-HCC therapeutic studies. However, to date, animal models with this advantage are extremely scarce. In this study, we developed a novel animal model for the fast assessment of drug efficacy against primary HCC in vivo. HCC was induced in immunocompetent hepatocarcinogenesis reporter (HCR) mice by diethylnitrosamine (DEN) injection and confirmed by histopathological staining. Using the bioluminescence imaging (BLI) technique, HCC progression was longitudinally visualized and monitored in a non-invasive way. Tests of two clinical drugs showed that both sorafenib and oxaliplatin significantly inhibited the BLI signal in mouse liver in a dose-dependent manner. The in vivo intensity of BLI signals was highly consistent with the final tumor burden status in mouse liver after drug treatment. The inhibitory effect of anti-HCC drugs was accurately evaluated through in vivo BLI intensity detection. Our study successfully established a bioluminescence mouse model for non-invasive real-time monitoring of HCC therapy, and this HCR mouse model would be a useful tool for potential anti-HCC drug screening and new therapeutic strategy development.

Introduction

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally, yet the development of effective treatments is hindered by the limitations of current animal models. Standard subcutaneous models fail to replicate the liver's complex microenvironment, while traditional orthotopic models require invasive procedures or animal sacrifice to monitor tumor growth. This study introduces a specialized Hepatocarcinogenesis Reporter (HCR) mouse model that allows for real-time, non-invasive monitoring of primary liver cancer progression and therapeutic response.

Methods

The researchers utilized HCR mice genetically engineered to express a luciferase reporter gene under the control of the endogenous Afp (alpha-fetoprotein) promoter. Because Afp is highly active in HCC but silenced in healthy adult livers, the mice produce light only where liver tumors are present.

  1. Induction: HCC was induced in immunocompetent HCR mice via a single injection of diethylnitrosamine (DEN).
  2. Imaging: Using Bioluminescence Imaging (BLI), the team quantified light intensity ($p/s/cm^2/sr$) emanating from the liver over several weeks.
  3. Drug Testing: The model was validated by treating mice with Sorafenib (a multikinase inhibitor) and Oxaliplatin (chemotherapy) to observe changes in the BLI signal.
  4. Validation: BLI intensity was compared against physical tumor measurements and histopathological (H&E) staining to confirm malignancy and quantify tumor burden.

Results

The HCR model successfully captured the natural progression of HCC. Longitudinal monitoring revealed a "critical period" of exponential growth between months 7 and 8 post-induction, which was clearly reflected in the rising BLI signals.

Figure 1: Longitudinal monitoring of HCC progression in HCR mice. (A) BLI intensity over 8 weeks. (B) Representative BLI images of mice. (C) Comparison of BLI overlay and physical photograph. (D) Histopathological confirmation of HCC.

Key findings from the study include:

  • Quantitative Correlation: Light intensity correlated strongly with actual physical tumor volume ($R^2 = 0.8208$ for Sorafenib), proving that BLI is a reliable proxy for tumor burden.
  • Dose-Dependent Inhibition: Both Sorafenib and Oxaliplatin significantly reduced the BLI signal compared to controls. Interestingly, 10 mg/kg of Oxaliplatin was more effective at inhibiting growth than 20 mg/kg of Sorafenib in this specific model.
  • Internal Controls: While Afp is also expressed in the adult male testis, the testis signal remained stable during treatment. This confirmed that the observed liver signal reduction was due to anti-tumor effects rather than a systemic loss of the reporter gene.

Discussion and Limitations

The HCR mouse model provides a powerful tool for high-throughput, non-invasive screening of anti-HCC drug candidates. By using immunocompetent mice, the model preserves the natural tumor-host relationship often lost in other systems.

However, the model has limitations, primarily the long induction time (7–8 months) required for DEN-induced tumors to develop. Additionally, while excellent for primary HCC, the study did not focus on tracking distant metastasis. Despite these factors, the ability to perform longitudinal studies on the same animal significantly reduces statistical noise and the number of animals required for research. This model represents a significant step forward in accelerating the development of new therapeutic strategies for liver cancer.

Summary updated

Abstract

Animal models play crucial roles in the development of anticancer therapeutics. The ability to quickly assess the localized primary hepatocellular carcinoma (HCC) status in a non-invasive manner would significantly improve the effectiveness of anti-HCC therapeutic studies. However, to date, animal models with this advantage are extremely scarce. In this study, we developed a novel animal model for the fast assessment of drug efficacy against primary HCC <i>in vivo</i>. HCC was induced in immunocompetent hepatocarcinogenesis reporter (HCR) mice by diethylnitrosamine (DEN) injection and confirmed by histopathological staining. Using the bioluminescence imaging (BLI) technique, HCC progression was longitudinally visualized and monitored in a non-invasive way. Tests of two clinical drugs showed that both sorafenib and oxaliplatin significantly inhibited the BLI signal in mouse liver in a dose-dependent manner. The <i>in vivo</i> intensity of BLI signals was highly consistent with the final tumor burden status in mouse liver after drug treatment. The inhibitory effect of anti-HCC drugs was accurately evaluated through <i>in vivo</i> BLI intensity detection. Our study successfully established a bioluminescence mouse model for non-invasive real-time monitoring of HCC therapy, and this HCR mouse model would be a useful tool for potential anti-HCC drug screening and new therapeutic strategy development.
BibTeX
@inproceedings{zhao2019non,
  author = {Zhu Zhao and Juji Dai and Yan Yu and Qian Zhang and Sai Liu and Guanmeng Huang and Zheng Zhang and Tianke Chen and Rulu Pan and Liting Lu and Wenyi Zhang and Wanqin Liao and Xincheng Lu},
  title = {{Non-invasive Bioluminescence Monitoring of Hepatocellular Carcinoma Therapy in an HCR Mouse Model}},
  booktitle = {Frontiers in Oncology},
  year = {2019},
  doi = {10.3389/fonc.2019.00864},
}
Figure